The Filing Desk

Connect Biopharma

CNTB · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

CNTB · Last close · November 19, 2026
$0.63
Value Connect Biopharma yourself

Connect Biopharma's revenue fell 99.8% to $0 million in fiscal 2025. Its operating margin was −90,740.6%, down from −86.2% a year earlier. Free cash flow was −$52 million. The diluted share count rose 0.8%.

Connect Biopharma Holdings Limited Latest fiscal year ended December 31, 2025 10-K filed March 31, 2026 · 0001835268-26-000013 Updated
Revenue
$0M
99.8%
Operating margin
−90,740.6%
90654.4 pts
Net income
−$56M
 
Free cash flow
−$52M
 
Return on equity
−82.7%
66.6 pts
Market cap
$40M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Connect Biopharma does

Connect Biopharma is a clinical-stage biopharmaceutical company based in San Diego, California. Clinical-stage means its drug candidate is still being tested in people and is not approved for sale. It is working on treatments for asthma and chronic obstructive pulmonary disease (COPD), two long-term lung diseases that make it hard to breathe.

Its drug candidate is rademikibart, an antibody designed to block interleukin-4-receptor alpha (IL-4Rα), a protein involved in inflammation. The company is focused on acute asthma, where it says about 50% of patients fail to improve on first-line treatments, and on COPD. It believes that, if approved, rademikibart could offer a way to treat patients during flare-ups and might reduce hospital stays and repeat emergency visits.

The company has no approved products and no product sales. It relies on raising money from investors, and it runs some clinical trials.

Its biggest risks, as it describes them

  • It has a short operating history, significant losses, and expects more losses.
  • Raising more capital may dilute shareholders or limit what the company can do.
  • Clinical development is lengthy and costly, and the outcome is uncertain.
  • Trouble enrolling patients could delay its trials.
  • Serious side effects, or regulators not accepting data from trials at international sites, could delay or stop development.
From Connect Biopharma's annual report on Form 10-K, filed March 31, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Connect Biopharma lost money in fiscal 2025: a net loss of $56 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments268791189444
Debt incl. finance leases—0000
Net debt (negative means net cash)—−79−118−94−44
Net debt to EBITDA—————
Debt to equity—0.0x0.0x0.0x0.0x
Interest coverage−5,450.4x−5,681.7x−3,002.4x——
Current ratio15.3x10.0x4.8x11.5x3.7x
Quick ratio15.3x10.0x4.8x11.5x3.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Connect Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4.4 million of Connect Biopharma shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
May 29, 2026James HuangDirectorBought150,000$2.48$372,000Form 4
Mar 31, 2026James HuangDirectorBought1,160,000$3.45$4.0 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—3 of 81 of 8
Rule of 40——−80,787.2%
Altman Z''−2.973.74−22.77
Accruals ratio−9.5%7.0%−5.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assetsFailFailFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassFail
F-score—3 of 81 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Connect Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Connect BiopharmaFY25−99.8%−90,740.6%−80,687.5%——1
aTYR PharmaFY25−19.1%−40,856.3%−32,664.7%———Compare
BioRestorative TherapiesFY25−10.3%−4,350.1%−3,031.7%———Compare
Cardiff OncologyFY25−13.2%−8,256.3%−6,402.5%——2Compare
PMGC HoldingsFY25——−1,080.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

7 years of figures

Fiscal yearFY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue————0260
Revenue growth——————−99.8%
Gross profit———————
Research and development——8097532938
Operating income——−98−119−69−22−58
Net income——−202−118−62−16−56
Diluted EPS (US$)——−3.88−2.15−1.13−0.28−1.00
Diluted shares (millions)17175255555556
Cash flow
Cash from operations——−84−102−48−24−51
Capital expenditure——44010
Free cash flow——−88−106−48−24−52
Dividends paid0000000
Share buybacks0010000
Acquisitions0000000
Stock-based compensation——97574
Balance sheet at fiscal year end
Cash and short-term investments—155268791189444
Debt incl. finance leases———0000
Total assets——29117412710156
Total liabilities——191626914
Shareholders' equity—−1572721581029242
Margins and ratios
Gross margin———————
Operating margin—————−86.2%−90,740.6%
Net margin—————−60.0%−86,687.5%
Free cash flow margin—————−93.6%−80,687.5%
Rule of 40 (growth + FCF margin)——————−80,787.2%
Return on capital————−178.2%——
Return on equity———−54.8%−47.8%−16.1%−82.7%
Return on assets———−50.8%−41.2%−13.7%−70.5%
Net debt to EBITDA———————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Connect Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Connect Biopharma.